[1]范卫君,张亮,张福君**,等.CT导向下125I粒子植入治疗复发性盆腔恶性肿瘤*[J].中国微创外科杂志,2007,07(2):127-129.
　Fan Weijun,Zhang Liang,Zhang Fujun,et al.CT guided 125I radioactive seeds implantation in the treatment of recurrent malignant pelvic tumors[J].Chinese Journal of Minimally Invasive Surgery,2007,07(2):127-129.
点击复制

CT导向下125I粒子植入治疗复发性盆腔恶性肿瘤*()
分享到：

《中国微创外科杂志》[ISSN:1009-6604/CN:11-4526/R]

卷:
07
期数:
2007年2期
页码:
127-129
栏目:
出版日期:
2007-02-20

文章信息/Info

Title:
CT guided 125I radioactive seeds implantation in the treatment of recurrent malignant pelvic tumors
作者:
范卫君; 张亮; 张福君**; 吴沛宏; 王俊杰①; 黄金华; 顾仰葵; 赵明; 李传行; 高飞
华南肿瘤学国家重点实验室中山大学肿瘤防治中心影像介入中心，广州510060
Author(s):
Fan Weijun;  Zhang Liang;  Zhang Fujun;  et al.
State Key Laboratory of Oncology in Southern China, Radiology Department, Cancer Center of Sun YatSen University, Guangzhou 510060, China
关键词:
肿瘤; 放射性粒子
Keywords:
Tumor; Radioactive seed
分类号:
R73；R817.8
文献标志码:
A
摘要:
目的探讨CT导向下125I粒子植入治疗复发性盆腔恶性肿瘤的疗效。方法18例复发性盆腔恶性肿瘤患者采用CT导向下125I放射性粒子植入。粒子植入之前采用TPS模拟布源或遵循Halarism的125I经验公式：mCi=Da×5，Da为靶组织长、宽、高的平均值（L+W+H）/3，单位为cm，求出术中所需125I粒子的总活度及算出治疗粒子的数量。在螺旋CT导向下将125I放射性粒子植入盆腔肿瘤内。结果全组18例22个病灶治疗后2个月后采用PETCT评价，完全缓解（CR）6例，部分缓解（PR）8例，稳定（NC）3例，进展（PD）1例。18例随访7~16个月，全部存活，近期平均生存期9.5个月。结论125I放射性粒子植入是治疗复发性盆腔恶性肿瘤的一种有效的方法。
Abstract:
ObjectiveTo explore the clinical efficacy of CT guided 125I seeds implantation in the treatment of recurrent malignant pelvic tumors.MethodsEighteen patients with recurrent malignant pelvic tumors were treated by spiral CT guided 125I radioactive seeds im

参考文献/References:

[1]李孟达.宫颈复发癌的诊断和治疗.实用妇产科杂志,1994，11(5):242.
[2]Temple WJ,Saettler EB.Locally recurrent rectal cancer:role of composite resection of extensive pelvic tumors with strategies for minimizing risk of recurrence.Surg Oncol,2000,73(1):47-58.
[3]万德森，主编.临床肿瘤学.第2版.北京:科学出版社,2005.181-182.
[4]Hong JH,Tsai CS,Lai CH,et al.Recurrent squamous cell carcinoma of cervix after definitive radiotherapy.Int J Radiat Oncol Biol Phys,2004,60(1):249-257.
[5]Moore DH,Blessing JA,McQuellon RP,et al.Phase III study of cisplatin with or without paclitaxel in stage IVB,recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study.J Clin Oncol,2004,22(15):3113-3119.
[6]Tsuda H,Hashiguchi Y,Nishimura S,et al.Phase III study of irinotecan (CPT11) plus nedaplatin (254S) with recombinant human granulocyte colonystimulating factor support in patients with advanced or recurrent cervical cancer.Br J Cancer,2004,91(6):1032-1037.
[7]Nag S,Ellis RJ,Merrick GS,et al.American Brachytherapy Society recommendations for reporting morbidity after prostate brachytherapy.Int J Radiat Biol Phys,2002,54(2):462-470.
[8]Sharma SK,Forgione H,Isaacs JH.Iodine125 interstitial implants as salvage therapy for recurrent gynecologic malignancies.Cancer,1991,67(10):2467-2471.
[9]Hockel M,Sclenger K,Hamm H,et al.Fiveyear experience with combined operative and radiotherapeutic treatment of recurrent gynecologic tumors infiltrating the pelvic wall.Cancer,1996,77(9):1918-1933.

更新日期/Last Update: 2013-11-15